Navigation Links
Genomic Health Announces Third Quarter 2011 Financial Results and Business Progress
Date:11/1/2011

ed 2011 net income guidance; the company's belief that it is on track to launch tests for DCIS and MMR by the end of 2011 and to initiate a clinical validation study of its prostate cancer test currently in development in 2011; the attributes and focus of the company's product pipeline, including the prospects for its next generation cancer diagnostic programs; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop, both domestically and abroad; our success in retaining current contracts or levels of reimbursement coverage for our tests; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; our ability to compete against third parties; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; our ability to successfully commercialize our products outside of the U.S.; our ability to obtain capital when needed; our ability to leverage our existing  infrastructure and generate net income while continuing to invest in future growth drivers; our history of operating losses; fluctuations in levels of growth; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the period ended June 30, 2011. These forward- lookin
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MUMBAI , Indien, August 1, 2014 ... ("Cipla") und BioQuiddity Inc. gaben heute bekannt, ... in regionalen Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen ... die das Gebiet der Europäischen Union und ... mit CE-Kennzeichnung versehene und mit Ropivacain gefüllte ...
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 28, 2014.  , Revenues were $10.6 million in ... in the 2013 second quarter and up sequentially from $10.3 ... first six months of 2014 were $20.9 million, up 15% ... year. , Gross margin for the quarter was 50.0%, ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... 27 Global pharmaceutical outsourcing has become ... supply chain environment that has pharmaceutical and life sciences ... co-sponsored by PwC US and published today by Axendia, ... the report, 50 percent of pharmaceutical and life sciences ...
... Essential Pharmaceuticals, LLC, a private company dedicated to ... sciences market, announced today that the Company will ... products: serum replacement, cryopreservation and clinical pathology media, ... Cell-Ess™ Serum Replacement cell culture medium, ...
Cached Medicine Technology:As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 2As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 3As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 4As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed 5Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical 2
(Date:8/1/2014)... Did you know that July was Sarcoma ... to raise awareness across the country and to educate people ... to the American Cancer Society, nearly 5,000 Americans are expected ... soft tissue sarcomas will be diagnosed. , “A lot ... are other kinds of cancer,” said Dr. Chawla, a physician ...
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, ... a newly released article entitled, “ 5 Signs That ... Replaced ,” Clean Crawls explains the need to replace ... by critters. , Get a free attic insulation ... http://www.cleancrawl.com/contact . , If crawl space or attic ...
(Date:8/1/2014)... 01, 2014 According to the Metabolic Switch ... comprehensive diet guide for women who want to lose weight ... protein rich foods and fat loss fruits that ... , Vkool writes in its review that this book is ... about fat burning hormones and weight loss supplements. , ...
(Date:8/1/2014)... The Multiple System Atrophy Coalition, a growing nonprofit 501 ... affected by the neurological disorder Multiple System Atrophy (MSA), announced ... to its Board of Directors. , Sharon was the primary ... was diagnosed officially with MSA in 2010 and passed away ... many others with this rare disorder it took several years ...
(Date:8/1/2014)... Blindness is a reversible ailment these days . ... despite well-meaning efforts, still have a long way to go ... blindness that does not involve any kind of health risk ... takes the “slack” from the mainstream by providing a cure ... , Alternative health specialist Kevin Richardson actually has the ...
Breaking Medicine News(10 mins):Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2
... that allows products to be traced through the U.S. supply chain might have helped contain the ... announced today. iGPS urged the U.S. Senate to mandate the latest tracking technology in legislation pending ... ... ...
... study recently published in Academic Emergency Medicine ... older to receive potentially inappropriate medications when treated in ... or 16.8 percent of eligible emergency visits from 2000-2006, ... PIMs. The large sample of approximately 470,000 ED and ...
... to their normal state of mind soon after they get ... No matter how cheerful you felt as you wiggled your ... how thrilled you were to finally lay eyes on that ... new research shows the happiness boost many experience while vacationing ...
... Dr. ... and Boca Raton, Florida. These sites provide important information on emergency services, treatments, and offer ... ... launched a new web site designed to reach more patients in Boca Raton. The ...
... March 12 O.N.E., One Natural Experience debuts ... water that goes the extra mile.  O.N.E. Active provides the ... the #1 selling super-hydrator, O.N.E. Coconut Water -- but with ... provides the added edge of sharpening the mind while engaging ...
... More players had ligament damage, ankle sprains than on ... News) -- Pro football players are more likely to ... an artificial turf called FieldTurf than on natural grass, ... the 2002-2008 National Football League seasons and found that ...
Cached Medicine News:Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 2Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 3Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 4Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 5Health News:Some older ER patients are getting the wrong medicines, U-M study finds 2Health News:Happy From Your Vacation? It Won't Last 2Health News:Happy From Your Vacation? It Won't Last 3Health News:Delray Beach and Boca Raton Veterinarian Launches New Web Sites for Atlantic Animal Hospital 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 3Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 4Health News:Football Injuries More Likely on Certain Artificial Turf 2
... wall stand and table configurations designed for ... Canon CXDI-40G can capture 17 X 17 ... angle. This flexible system includes a Bucky ... and a ceiling suspended multi-positioning unit. Versatile ...
The Oscor PACE 203 H is the third generation of Osypka line of External Dual Chamber Pacemakers. Based on over 20 years of pacing experience, the PACE 203 H represents todays standard in temporary du...
... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
... The TME 227 T is ... for temporary cardiac pacing and ... surgery. The TME 227 T ... the myocardium, which allows safe ...
Medicine Products: